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1. Despite a rapidly growing research interest in FCR, lack of consensus on definition and measurement 
including clinical FCR, sparse model development and testing, and limited available clinical interventions 
have impeded knowledge transfer into patient services.  
2. To move forward, a 2-day colloquium was held in Ottawa, Canada in August 2015 to progress 
knowledge and identify future research directions. 
3. A comprehensive research program was proposed, including development of a clinical definition, an 
updated review of screening measures, and a review of existing interventions. 
4. A new special interest group was created with the International Psychosocial Oncology Society (IPOS) 
to facilitate the implementation of this research program and future international collaborations. 
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Fear of cancer recurrence (FCR) has been described as the sword of Damocles that hangs over 
survivors for the rest of their lives [1]. FCR is usually defined as “the fear or worry that the cancer will 
return or progress in the same organ or in another part of the body” [2,3]. FCR was the first or second 
most commonly reported problem by patients with breast, ovarian, colon, lung, or prostate cancer [4]. 
Overall, the current literature suggests that moderate to high levels of FCR, suggestive of clinical FCR, 
affect 49% of cancer patients [5] and that severe FCR tends to persist over time [6]. FCR is consistently 
associated with increased functioning impairment, psychological distress, stress-response symptoms, 
and lower quality of life [5-7], yet is distinct from other anxiety disorders [8]. High FCR is also associated 
with greater utilization of healthcare resources, thus suggesting that untreated FCR is likely to increase 
cost to the healthcare system [9].  
Despite clear evidence that cancer patients with higher FCR have higher psychological morbidity 
and may incur additional medical costs, we believe there are numerous gaps in the current literature 
that need addressing for the field of FCR research and intervention to progress. These include reaching 
consensus on 1) definitions of FCR and clinical FCR; 2) whether to and how to screen for clinical FCR; 3) 
which measures to use in the clinical setting; 4) which model(s) to use to guide interventions, 5) and 
how to manage this problem clinically. To start addressing these gaps and propose a coherent research 
agenda, a two-day Colloquium on FCR was held in Ottawa, Canada, on August 3 and 4th, 2015 to bring 
together international researchers, policy makers, and patient advocates. See Table 1 for a summary of 
objectives and the proposed research program emerging from the meeting.  
Objective 1: Agreeing on a definition of FCR and on the diagnostic characteristics of clinical FCR 
While the above definition is often used, there is no consensus among researchers that it 
adequately describes the phenomenon of FCR. For example, this definition does not reflect that FCR is a 
normal reaction to cancer. Also, the existing definition of FCR does not fit well with recent advances in 
cancer medicine. Therapies may be ongoing for many years and cancer is more and more seen as a 
chronic illness. As such, attendees of the FCR colloquium reviewed currently used definitions for 
accuracy and completeness and reached a consensus on a new definition of FCR using a Delphi study 
method [Lebel et al. Submitted].   
Also, while there is consensus that FCR ranges from “normal” to “clinical”, there is no 
agreement about what constitutes a clinical level of FCR. Discussion between researchers and clinicians 
is required to enable agreement on the diagnostic characteristics of clinical FCR. Attendees discussed 
the consequences of diagnostic labelling.  While it was recognised that a clinical diagnosis may be 
stigmatising, attendees felt a clinical cut-off would: (i) instigate effort to assist patients with higher than 
average levels of FCR, (ii) prevent unnecessary use of limited resources and (iii) focus research activity to 
those with problematic recurrence fears.   Attendees identified elements of clinical FCR based on their 
clinical experience and the existing literature [Lebel et al. Submitted]. These elements will be refined in a 
second Delphi study.  
 
Objective 2: Measuring clinical FCR 
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The absence of an agreed upon definition of clinical FCR has made the assessment of this 
phenomenon challenging. Studies that attempt to define clinical FCR, such as the proposed Delphi study, 
will draw together informed opinion to arrive at a best fitting solution. Such a development would 
facilitate efforts to create measures of ‘clinical’ FCR comprising: (i) self-report questionnaires and/or (ii) 
standardised interview procedures.  It will be important for such measures to specify: the formality of 
the procedure, the assessor, timing (e.g., first follow-up and frequency of repeat assessment), setting 
conditions (e.g., oncology clinic), length, complexity, and measurement conceptual structure.   
Some FCR instruments have cut-off scores to identify “high” or “clinical” FCR [5, 10], but the lack 
of a gold-standard clinical interview or measure makes validating cut-offs difficult. A clinical interview 
was developed and used to validate the cut-off score of the Fear of Cancer Recurrence Inventory-Short 
Form [11] but we need to further validate its content and consider modifying it to reflect agreed upon 
definitions of FCR and clinical FCR. A gold-standard interview to detect clinical FCR is essential to assess 
the sensitivity and specificity of available FCR measures at detecting clinical FCR.  
Objective 3: Creating guidelines in the use and implementation of FCR measures in a clinical setting  
There are over 30 FCR measures available to researchers and clinicians [12]. While some 
instruments have been recommended for clinical and research use based on available evidence of their 
strong psychometric properties, they are currently not being routinely used by oncology centers to 
assess FCR among their patients.   
The next step is the development and validation of short screening measures that can be used in 
clinical settings. There are newly-developed brief measures which may prove promising for FCR 
screening, validated amongst colorectal [13], breast [10,14], prostate [vd Wal et al. Unpublished] and 
head and neck cancer survivors [15]. We need studies that assess how we can incorporate such 
measures into routine screening efforts. Additional research priorities for this topic area are summarized 
in Table 1.  
Objective 4: Elaborating and/or refining theoretical models   
There is a growing body of research on predictors and correlates of FCR, as evidenced by the 
recent publication of three reviews of the literature on this topic [5-7]. However, while more than 40 
predictors of FCR have been studied [6], few have been identified as “strong” predictors of FCR. The 
exceptions are younger age, which is not amenable to change, and presence of somatic symptoms. 
These disparate findings can be explained by the lack of available models of FCR. Until recently, there 
was only one proposed model of FCR [16], which has not yet been empirically validated. Newer 
therapeutic models have been proposed [17,18] and could be used to guide model studies. A research 
priority is to identify the basic common elements of therapeutic FCR models and start empirically 
validating their proposed relationship with FCR. For example, the first results on metacognitions and 
implicit processes show that these may be promising mechanisms to consider [19]. 
Objective 5: Next steps for interventions 
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Despite the high prevalence of FCR and its impact on the patient and the health care system, a 
recent study showed that oncology specialists refer only 21% of patients with high FCR for psychosocial 
services and are unsure about the best approach to treat this common problem [20]. Fortunately, 
several interventions are currently being tested in randomized controlled trials, which hopefully will lead 
to evidence based guidelines on how to manage FCR in the near future. These are specifically designed 
to alleviate clinical or moderate to high FCR, and are largely based on a cognitive-behavioral model of 
psychotherapy. However, each intervention includes unique ingredients (e.g. meta-cognitive therapy or 
exposure) and format of delivery (e.g. group, blended care, individual). At this point, research is needed 
to identify the active ingredients in current FCR interventions. Additional research priorities within this 
topic are summarized in Table 1. 
Objective 6: Formally structuring researchers interested in FCR as a research group 
To ensure continued optimal development of this research area, a Special Interest Group under 
the banner of the International Psycho-Oncology Society, called FORwaRdS (the Fear Of RecuRrence 
Special interest group) was created.  
CONCLUSION 
Several concrete projects are planned following an expert and stakeholders meeting to address 
gaps in the literature on FCR. The proposed program of research will hopefully lead to guidelines being 
available in the near future to orient clinical care for cancer patients struggling with FCR.   
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Table 1. Proposed program of FCR research  
Objective Future research steps and recommendations 
Agreeing on a 
definition of FCR and 
on the diagnostic 
characteristics of  
clinical FCR 
 Publish the new definition of FCR and the elements of clinical FCR 
identified during the Colloquium 
Measuring clinical FCR  The elements identified to describe clinical FCR will be submitted 
to researchers and clinicians using a formal Delphi survey  
 Following the results of this survey, a ‘gold standard’ interview will 
be proposed and tested  
Creating guidelines in 
the use and 
implementation of 
FCR measures in a 
clinical setting 
 An updated systematic review of FCR measures focussing on 
recommendations about measures to use for screening, case-
finding and intervention purposes will be written up 
 Developing cross-culturally valid short screening instruments and 
longer instruments that reflect definitions of FCR and clinical FCR  
across diverse range of respondents (including carers), cultures, 
and languages is a priority 
Elaborating and/or 
refining theoretical 
models   
 Testing (segments of) models and developing experimental 
paradigms are a priority 
Next steps for 
interventions 
 A literature review on existing interventions will be written up 
 The following are identified as priorities: 
o Testing if tailored interventions are more effective than 
generic interventions at addressing FCR 
o Studying the effect of couple- and family-focused 
interventions on FCR  
o Evaluating possible iatrogenic effects of FCR interventions 
Formally structuring 
researchers interested 
in FCR as a research 
group  
 Forming a new special interest group as part of International 
Psycho-Oncology Society 
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